Natera (NASDAQ:NTRA) Price Target Raised to $330.00 at Canaccord Genuity Group

Posted by Stanley Muller on Jul 14th, 2026

Natera (NASDAQ:NTRA – Get Free Report) had its target price raised by investment analysts at Canaccord Genuity Group from $285.00 to $330.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 20.93% from the company’s previous close.

Several other equities research analysts have also recently issued reports on NTRA. Piper Sandler reaffirmed an “overweight” rating and set a $249.00 target price on shares of Natera in a research note on Tuesday, May 12th. Sanford C. Bernstein assumed coverage on shares of Natera in a research report on Friday, June 26th. They set an “outperform” rating and a $310.00 price target on the stock. UBS Group set a $260.00 price objective on shares of Natera in a research note on Wednesday, June 24th. Wells Fargo & Company increased their price target on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Finally, The Goldman Sachs Group initiated coverage on Natera in a research report on Friday, June 5th. They set a “neutral” rating and a $245.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $267.83.

Check Out Our Latest Stock Report on Natera

Natera Price Performance

Shares of NASDAQ:NTRA opened at $272.89 on Tuesday. Natera has a 1 year low of $131.81 and a 1 year high of $288.04. The firm has a market capitalization of $39.08 billion, a PE ratio of -167.42 and a beta of 1.51. The business’s 50 day moving average price is $228.87 and its 200-day moving average price is $219.24.

Insiders Place Their Bets

In other news, Director Gail Boxer Marcus sold 11,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the sale, the director owned 6,183 shares in the company, valued at $1,343,009.43. This trade represents a 64.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Rowan E. Chapman sold 2,964 shares of Natera stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $216.78, for a total transaction of $642,535.92. Following the sale, the director directly owned 3,124 shares in the company, valued at approximately $677,220.72. The trade was a 48.69% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 178,872 shares of company stock worth $39,627,696. 5.05% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Natera

Hedge funds have recently modified their holdings of the business. Coatue Management LLC increased its position in shares of Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after purchasing an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP raised its holdings in Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after buying an additional 2,420,263 shares during the period. Norges Bank purchased a new position in Natera during the fourth quarter worth about $372,398,000. JPMorgan Chase & Co. boosted its stake in Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after buying an additional 1,225,420 shares during the period. Finally, AQR Capital Management LLC increased its position in shares of Natera by 39.0% during the third quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock valued at $386,338,000 after acquiring an additional 673,315 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.